Interferon alfa-2b/Ribavirin

N/A

Report date: 2022/02/14 14:12:58

Base Information

Drug NameInterferon alfa-2b/Ribavirin

Drug Alias Name干扰素α-2b/利巴韦林Interferon α-2b/ribavirinIFN α-2b/ribavirinIFN-alfa2b/ribavirinRebetron

ClassificationBiologics

Mechanisms of ActionInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitorsInterferon alpha/beta receptor agonistsBacterial DNA-directed RNA polymerase inhibitors +[4]

TargetsInosine-5'-monophosphate dehydrogenase (IMPDH)Interferon alpha/beta receptorBacterial DNA-directed RNA polymerase +[4]

Therapy Area/IndicationsHepatitis C

Global Approved IndicationsHepatitis C

Approved Indications in ChinaN/A

Original Approved Country/TerritoryUnited States

Original Approved Date1998/01/01

Country/TerritoryCanadaUnited StatesItaly +[6]

CombinationsYes

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesMerck Sharp & Dohme Corp

China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme Corp

Inactive CompaniesN/A

Active IndicationsHepatitis C

Inactive IndicationsN/A

Other Information

ATC CodeS01AD05